Navigation Links
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Date:10/5/2009

17 of these patients were deemed evaluable. In this initial cohort, 11 of the 17 evaluable patients achieved an objective tumor response by the time that treatment with the combination of bavituximab, carboplatin and paclitaxel was completed. These initial results exceeded the pre-specified endpoint needed to expand the trial, which then enrolled an additional 28 patients to reach the planned study total of 49 patients.

Secondary objectives of the study include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria. Patients may continue to receive bavituximab as a monotherapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in India according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

Lung cancer is a major cause of cancer deaths worldwide. According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in men and women in the U.S. and is the leading cause of cancer deaths. It estimates that in 2009, there will be approximately 219,440 new cases of lung cancer in the U.S. and an estimated 159,000 lung cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases.

Bavituximab is a monoclonal antibody that targets the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By masking PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab is being tested in combination with chemotherapy in three Phase
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... developed a technique for controlling the surface tension of ... door to a new generation of reconfigurable electronic circuits, ... fact that the oxide "skin" of the metal ... a surfactant, lowering the surface tension between the metal ... liquid metal alloy of gallium and indium. In base, ...
(Date:9/15/2014)... idea of fibers made of carbon nanotubes is neat, but ... The single-walled carbon nanotubes in new fibers created at Rice ... process designed by chemist Angel Mart and his colleagues. , ... results this month in the journal ACS Nano , ... together into a fiber. , Left to their own devices, ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 Bioptigen ... deep imaging OCT system for the optical device metrology ... EnvisuTM S4410 SDOCT for Contact Lens Metrology ... standard and high complexity contact lens, IOL structures, and ... of a complete contact lens immersed in a hydration ...
(Date:9/15/2014)... Idaho , Sept. 15, 2014  iVinci Health ... only comprehensive Patient Revenue Management system, branded as VisitPay®, ... company also announced the launch of a new extension ... that provides an easy and convenient way for patients ... for balances owed by them and their families. ...
Breaking Biology Technology:Researchers control surface tension to manipulate liquid metals 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3
... BEIJING , Feb. 8 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") ... participate at the,following investor conferences in March 2010 : , , Investor Conference ... Location, Rodman & Renshaw Annual ... ...
... , Full enrollment occurs five months ahead of ... 8 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... Phase 2 clinical study of its lead drug RVX-208. "The ... full 5 months ahead of our original schedule, is a ...
... ... agency, announced today that it has been selected by Invida Group, the leading provider ... communications and public relations program. , ... Salem, MA (Vocus) February 8, 2010 -- LaVoie Group , ...
Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 4Invida Selects LaVoie Group as Public Relations Agency of Record 2Invida Selects LaVoie Group as Public Relations Agency of Record 3
(Date:9/15/2014)... is a vital source of energy for both plants ... its way into the cell could lead to the ... increase in the amount of fruits and vegetables farmers ... uncovered one of these "pathways" into the cell by ... a strand of spider silk. , To determine the ...
(Date:9/15/2014)... issue of the journal Science comes out, ... Montana and even the Netherlands, thanks to the type ... norm in these connected times. Yes, the research was ... in biology, medicine, biotechnology and agriculture. It could save ... that one, that one knew another one, and brilliant ...
(Date:9/15/2014)... reef ecologists fears that reef biodiversity may not provide ... once thought. , In an international study published today, ... for Coral Reef Studies (Coral CoE) says we need ... reef ecosystems. , In coral reefs, just as in ... the ecosystem safe and functioning. , Professor Bellwood ...
Breaking Biology News(10 mins):X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Collaboration drives achievement in protein structure research 2Specialized species critical for reefs 2
... of infection in some hospital wards varies dramatically according ... A University of Leeds-led team studied airflow in a ... two rows of up to 30 bedsby using tracer ... found ventilation in the ward was generally good when ...
... CITY, Calif. , April 16, 2013   DigitalPersona, ... solutions, today announced that Papa John,s restaurants in ... fingerprint biometrics to speed and secure employees, and managers, ... in northern China are using ...
... April 16, 2013 Studies have shown that about ... (HIV) have an elevated resting energy expenditure (REE). Their ... body temperature, and breathing. Most studies have been conducted ... small sample sizes. A team of researchers has sought ...
Cached Biology News:Energy efficiency could increase infection risks in hospital wards 2Energy efficiency could increase infection risks in hospital wards 3Papa John's Restaurants in China Speed and Secure Workflow with DigitalPersona Fingerprint Biometrics 2Women with HIV shown to have elevated resting energy expenditure 2
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Mycoplasma and virus tested...
Biology Products: